Cardinal Health (CAH) Stock Looks Strong On Returns Yet Above Fair Value

Cardinal Health has delivered very strong share price gains over the past five years, yet its current valuation checks lean expensive, which raises the question of how much of that strength is already reflected in the stock.

• Cardinal Health has returned about 365.1% over five years. This puts extra focus on whether today’s price still offers an appealing entry point or mainly reflects past gains.
• Recent enthusiasm around Cardinal Health’s specialty healthcare and higher margin growth businesses can support richer expectations. At the same time, ongoing competitive and regulatory pressures may limit how much investors are willing to pay for those prospects.
• With a value score of 2 out of 6, Cardinal Health does not screen as a clear bargain on the broader valuation checks.

The issue now is whether Cardinal Health’s current valuation still leaves enough room for a compelling long term return after such a strong run.

Cardinal Health delivered 46.0% returns over the last year. See how this stacks up to the rest of the Healthcare industry.

Does Cardinal Health Look Pricey on Earnings?

The P/E ratio is a common way to judge how much investors are paying for each dollar of Cardinal Health’s earnings, which fits a mature, profit-generating business like this.

Cardinal Health trades on a P/E of about 35.2x, compared with a healthcare industry average of roughly 24.9x and a peer average of about 27.8x. The model based fair P/E ratio for Cardinal Health is 29.2x, which is lower than where the stock currently sits, suggesting investors are already paying a premium relative to what its earnings profile might normally support.

Because Cardinal Health has been highlighted recently for strong execution and segment growth, the market may be comfortable with this higher earnings multiple, but it still prices the shares at a richer level than both peers and the tailored fair value estimate.

On the P/E multiple, Cardinal Health stock currently screens as overvalued compared with both its fair ratio and the broader healthcare group.

See what the numbers say about this price — find out in our valuation breakdown.

The Cardinal Health Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Cardinal Health pick up where the valuation puzzle leaves off by spelling out which combinations of future growth, margins and earnings would need to hold for the stock to be worth materially more or less than today’s price. Each narrative ties a fair value estimate to a particular set of potential catalysts and risks on Cardinal Health's Community page, so you can later see which version of events appears to be taking shape.

Share a Narrative on Cardinal Health to add your voice to the Simply Wall St community. Lay out a number driven view on whether developments like its removal from certain Russell indices and its specialty healthcare focus support today’s valuation.

You can set out the key drivers you think matter most for Cardinal Health's future, and then track how that thesis holds up as new results and news arrive.

Do you think there's more to the story for Cardinal Health? Head over to our Community to see what others are saying!

The Bottom Line

For Cardinal Health, the valuation work points to a stock that already assumes a lot is going right, with the current P/E premium doing most of the heavy lifting. The broader checks lean toward overvalued, which means the margin for error on future execution, competitive pressures and regulatory risks looks narrower than it did in the past. What matters most from here is whether Cardinal Health can sustain the earnings profile that investors are now paying up for or whether the multiple eventually settles closer to peers if that confidence eases.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com